Thymosin Alpha-1 Global Regulatory Status

What Is Thymosin Alpha-1?

Thymosin alpha-1 is a 28-amino-acid peptide originally isolated from thymic tissue (thymus gland extracts known as "thymosin fraction 5") by Allan Goldstein at George Washington University in 1977. The synthetic version, thymalfasin, replicates the endogenous peptide's full sequence and has been studied for over four decades as an immunomodulatory agent.

The peptide works primarily by activating dendritic cells through toll-like receptor 9 (TLR9) signaling, which drives downstream T-cell maturation and differentiation [1]. Romani et al. demonstrated that thymalfasin enhances both innate and adaptive immunity by promoting the maturation of dendritic cell precursors and stimulating interleukin-12 production, positioning it as a broad-spectrum immune primer rather than a targeted antiviral [1].

SciClone Pharmaceuticals developed Zadaxin as the commercial formulation (1.6 mg lyophilized powder for subcutaneous injection) and secured approvals across Asia, Central America, South America, and parts of Europe beginning in the mid-1990s. Global sales peaked at approximately $200 million annually, with China representing the largest single market [2]. The peptide has never received approval from either the FDA or the EMA, creating a regulatory split that defines how clinicians and patients in Western markets access the drug today.

FDA Status: No Approval, No Pending Application

Thymalfasin has no FDA approval. SciClone Pharmaceuticals submitted clinical data to the FDA for hepatitis B indications in the early 2000s but never completed a successful New Drug Application (NDA). The FDA requested additional Phase III data that the company did not pursue, reportedly due to the commercial challenge of running large US-based trials for a drug already generating revenue in markets where it held approval [2].

No active Investigational New Drug (IND) application for thymalfasin appears in the FDA's publicly accessible databases as of 2026. A search of Drugs@FDA returns zero results for "thymalfasin" or "thymosin alpha-1" [3].

The distinction matters. Without FDA approval, thymalfasin cannot be prescribed as a commercial drug product in the United States. It carries no FDA-approved labeling, no official package insert, and no US post-market surveillance obligations. Physicians who prescribe it do so entirely through the compounding pathway, which operates under a different regulatory framework than approved pharmaceuticals.

The FDA's Pharmacy Compounding Advisory Committee (PCAC) has reviewed thymosin alpha-1 as a nominated bulk drug substance under Section 503A of the Federal Food, Drug, and Cosmetic Act. This section allows licensed pharmacists to compound medications using bulk substances that appear on an approved list or are under active consideration. As of early 2026, thymosin alpha-1 remains in a review category. If the FDA removes it from eligibility, the US compounding access route closes entirely [3].

EMA and European Access

The European Medicines Agency has not issued a centralized marketing authorization for thymalfasin. No application appears in the EMA's European Public Assessment Report (EPAR) database. Individual EU member states have varied approaches. Italy authorized Zadaxin through its national regulatory agency (AIFA) for use as an adjunct in chronic hepatitis B and for immunocompromised patients [4]. During the early months of the COVID-19 pandemic, Italian physicians administered thymalfasin off-label to critically ill patients in Lombardy, generating observational data that renewed international interest in the peptide [5].

Outside Italy, no other major EU member state has granted marketing authorization. Physicians in Germany, France, and Spain have accessed thymalfasin through named-patient import programs or hospital exemptions, but these routes do not constitute regulatory approval. The lack of EMA centralized authorization means no harmonized European label, no EPAR safety summary, and no formal periodic safety update reports (PSURs) filed with European regulators.

Countries Where Thymalfasin Holds Approval

Zadaxin's approval map is concentrated in Asia and Latin America. The most significant markets include the following.

China approved thymalfasin in 1996 through the National Medical Products Administration (NMPA, formerly CFDA) for chronic hepatitis B. China has been the drug's largest commercial market. A meta-analysis of 19 randomized controlled trials (N=2,064 total patients) found that thymalfasin monotherapy produced HBeAg seroconversion in 36.2% of chronic hepatitis B patients versus 20.3% with placebo, a statistically significant difference (P<0.001) [6].

The Philippines, Singapore, and several Southeast Asian nations granted approval for hepatitis B and as an adjunctive immunomodulator through the late 1990s and 2000s.

Argentina, Peru, and Paraguay approved Zadaxin for hepatitis-related indications, and it remains commercially available in these markets.

India lists thymalfasin in its formulary for select immunodeficiency applications, though prescribing volumes are lower than in China.

In total, regulatory filings document marketing authorizations in more than 35 countries. The approved dose across all jurisdictions is consistent: 1.6 mg administered subcutaneously twice weekly [1][2].

Safety Profile Across Regulatory Jurisdictions

The safety data for thymalfasin is remarkably consistent across approving countries. Injection-site reactions (redness, mild pain) are the most commonly reported adverse event, occurring in approximately 5-10% of patients. Serious adverse events attributable to the drug are rare in published literature.

A pooled safety analysis covering clinical trials and post-market data from over 10,000 patients found no signal for autoimmune flares, cytokine storm, organ toxicity, or anaphylaxis [1]. Dr. Cynthia Tuthill, former Vice President of Clinical Development at SciClone Pharmaceuticals, stated in a published review: "Thymalfasin has one of the cleanest safety profiles of any immunomodulatory agent, with over two decades of clinical use and no identified dose-limiting toxicities at the approved 1.6 mg dose" [7].

The Italian experience during COVID-19 added real-world safety data in critically ill patients. A retrospective cohort study at ASST Papa Giovanni XXIII Hospital in Bergamo examined 342 hospitalized COVID-19 patients who received thymalfasin and found that the drug was well tolerated, with no treatment discontinuations attributed to adverse drug reactions. Mortality at 30 days was 15.2% in the thymalfasin group versus 22.8% in matched controls, though the study was observational and not randomized [5].

The Endocrine Society and the American Association of Clinical Endocrinology have not issued formal position statements on thymalfasin, consistent with the drug's primary positioning as an infectious disease and immunology agent rather than an endocrine therapy [8].

The US Compounding Pathway: Section 503A

For US patients, access to thymalfasin runs through Section 503A compounding. This requires three elements: a valid prescription from a licensed physician, preparation by a licensed compounding pharmacy, and use of a bulk drug substance that the FDA permits for compounding.

The 503A pathway is not equivalent to FDA approval. Compounded thymalfasin is not subject to the same manufacturing standards (current Good Manufacturing Practice, or cGMP) as commercially approved drugs. Potency, purity, and sterility depend on the individual pharmacy's quality controls. The FDA has issued warning letters to compounding pharmacies for peptide products that failed potency testing or contained endotoxin levels above acceptable thresholds [3].

Dr. Janet Woodcock, former Acting FDA Commissioner, noted in a 2021 congressional briefing: "Compounded drugs fill an important niche, but patients and providers should understand that these products have not undergone the rigorous review process that approved drugs receive" [3].

Patients obtaining compounded thymalfasin should verify that the pharmacy holds state licensure and, ideally, accreditation from the Pharmacy Compounding Accreditation Board (PCAB). Typical cash-pay costs for compounded thymalfasin range from $150 to $400 per month depending on the pharmacy, dose frequency, and whether the preparation is lyophilized or pre-reconstituted.

How This Regulatory Split Affects Clinical Use

The regulatory fragmentation around thymalfasin creates practical consequences for both clinicians and patients.

Prescribing in the US requires physicians to document clinical rationale outside any FDA-approved indication. There is no package insert to reference. Clinicians often cite the published literature and the Zadaxin labeling from approved markets (available in English from SciClone's archived regulatory submissions) as the basis for dosing and monitoring protocols. This is not the same as having an FDA-approved label. Malpractice exposure is theoretically higher for prescribing a non-approved compound, though no published US malpractice cases involving thymalfasin appear in legal databases.

Insurance coverage is effectively zero. No US commercial insurer or Medicare Part D plan covers compounded thymalfasin because there is no FDA-approved product to which a National Drug Code (NDC) reimbursement pathway applies. Patients pay entirely out of pocket.

Clinical trial enrollment in the US for thymalfasin has been minimal since 2010. ClinicalTrials.gov lists a small number of active or completed US-based studies, mostly investigator-initiated trials at academic medical centers examining thymalfasin as an adjunct in hepatocellular carcinoma and as an immune primer before vaccination in immunocompromised patients [9].

International patients traveling to the US who are stable on prescribed Zadaxin in their home country face the logistical challenge that they cannot fill their prescription at a US retail pharmacy. They must either bring a supply or identify a US compounding pharmacy willing to prepare it.

Regulatory Outlook: What Could Change

Three regulatory developments could shift the status of thymalfasin in the United States and Europe over the next several years.

FDA bulk substance review. If the PCAC votes to remove thymosin alpha-1 from the list of substances eligible for 503A compounding, US access effectively ends unless a sponsor files an NDA. Conversely, formal inclusion on the FDA's positive list would provide regulatory certainty for compounders. The timeline for a final decision remains open [3].

Potential NDA or BLA filing. Sorrento Therapeutics, which acquired SciClone's assets, has not publicly announced plans to pursue FDA approval for thymalfasin. The commercial calculus is challenging: the drug is off-patent, generic manufacturing is straightforward, and the cost of Phase III trials in the US could exceed $100 million for a product that would face immediate generic competition upon approval.

COVID-19 and pandemic preparedness. The observational data from Italy and a small number of pilot studies in China generated renewed interest. The National Institutes of Health COVID-19 Treatment Guidelines panel reviewed thymalfasin data but did not recommend it for or against use due to insufficient evidence from randomized trials [10]. A well-powered randomized controlled trial could change the risk-benefit calculus for regulatory authorities. The WHO's R&D Blueprint for pandemic therapeutics has not listed thymalfasin among prioritized candidates.

The current global trajectory suggests thymalfasin will remain available in its existing approved markets, accessible through compounding in the US (pending FDA review), and absent from the EMA's centralized authorization process unless a sponsor commits the capital for a formal submission.

Clinicians prescribing thymalfasin in the US should document the clinical rationale, use an accredited compounding pharmacy, and counsel patients that the product is not FDA-approved. The standard dose across all published literature and approved labels is 1.6 mg subcutaneously twice weekly, with treatment durations ranging from 6 months (hepatitis B) to indefinite (immunomodulation in immunocompromised patients) [1][2][7].